Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of ALOXI® (palonosetron hydrochloride) Injection approved by the U.S. Food and Drug Administration (USFDA).
The ALOXI® brand and generic had U.S. sales of approximately $446 million MAT for the most recent twelve months ending in January 2018 according to IMS Health*.
Dr. Reddy’s Palonosetron Hydrochloride Injection is available in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial.
ALOXI® is a registered trademark of Helsinn Healthcare SA.
*IMS National Sales Perspective: Retail and Non-Retail MAT January 2018